Remove 2029 Remove Competition Remove Safety
article thumbnail

EHA 2023: Kura Oncology’s menin inhibitor ziftomenib shows impressive Phase I results

Pharmaceutical Technology

As for safety, 85% had at least one Grade 3 or higher treatment-emergent adverse event (TEAE). According to GlobalData’s analyst consensus forecast, global sales for ziftomenib will reach $255m by 2029. Kura faces competition in the menin inhibitor market as the therapy is being developed to treat various indications.

article thumbnail

Key Developments from AMCP 2023 on Blockbuster Generics, Diabetes Drugs, PBM Legislation, and More

PM360

Attention deficit hyperactivity disorder (ADHD) drug Vyvanse (lisdexamfetamine dimesylate) , manufactured by Takeda, also is facing generic competition. In the respiratory area with inhalers, it’s tough to get drugs approved, so the competition comes slowly,” he said. Starting in 2026, the provision will affect 10 Part D drugs.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Emerging Trends in Orthopedic Medical Device Industry

Medico Reach

billion by 2029. From procedure efficacy and cost to safety and training, there are still several challenges to overcome before robot-assisted surgery becomes standard practice. The potential increase in industry competition could also spell trouble for some. There is a caveat here, though.

Medical 98
article thumbnail

T2D market growth driven by novel GLP-1RAs and once-weekly basal insulin therapies

Pharmaceutical Technology

Type 2 diabetes (T2D) is a crowded and competitive landscape with multiple “me-too,” generic and biosimilar drugs entering the market, with market growth primarily driven by an increasing prevalent population across nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, China, and India).

article thumbnail

Emerging Trends in Orthopedic Medical Device Industry

Medico Reach

billion by 2029. From procedure efficacy and cost to safety and training, there are still several challenges to overcome before robot-assisted surgery becomes standard practice. The potential increase in industry competition could also spell trouble for some. There is a caveat here, though.

Medical 52